Xconomy: East Coast Biotech Roundup: Foundation, Biogen, Moderna, & Lots More
Summary
Agios holds U.S. rights to the drug; it could also get up to $120 million in milestones from Celgene should AG-120 continue to progress, and royalties on sales internationally.—Cambridge-based Lysosomal Therapeutics, the startup founded by Kees Been with the help of Atlas Venture and former Genzyme CEO Henri Termeer last year to go after therapies for Parkinson’s and Gaucher Disease, is in the midst of raising a Series A round that could close this month, Alex Lash reports.—Boston-based Ziopharm (NASDAQ: ZIOP) became the latest biotech to add CAR-T (a cellular immunotherapy taking the cancer treatment world by storm) to its ledger.Apparently, as FierceBiotech reported, diving into the increasingly competitive market for nonalcoholic steatohepatitis, or NASH therapies.Intercept Pharmaceuticals burst onto the scene last year with promising data for a NASH drug, and others have since joined the fray.